Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Researchers identify strategy for overcoming resistance to RAS-targeted cancer drugs

2 November 2026 · By · Wire by Fusion42

Published

2 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medicalxpress.com →

◆ Verified

Fusion42 · 2 November 2026 · Fusion42 review

Researchers at Roswell Park Comprehensive Cancer Center found that resistance to KRAS-targeted cancer therapies is linked to persistent cell-cycle activity in cancer cells, which can be overcome by combining RAS inhibitors with CDK4/6 or CDK2 inhibitors to produce more durable tumour control.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now explore combining KRAS inhibitors with CDK4/6 or CDK2 blockers to tackle resistance that halts treatment success. This opens a new path to extending patient response times and could set a new standard in cancer drug regimens.

◆ Coverage

1 source · 2 Nov 2026

◆ Related on Wire

◆ Topics

Biotechcancerdrug-resistanceras-inhibitorscdk-inhibitorsoncology